Gene Symbol | RWDD3 |
---|---|
Entrez Gene | 25950 |
Alt Symbol | RSUME |
Species | Human |
Gene Type | protein-coding |
Description | RWD domain containing 3 |
Other Description | RWD domain-containing protein 3|RWD domain-containing sumoylation enhancer|RWD-containing sumoylation enhancer |
Swissprots | Q08AJ7 Q6FID3 Q9BX35 C9JI45 A6NP44 C9J9L7 A8K9F0 Q9Y3V2 |
Accessions | EAW73019 EAW73020 EAW73021 EAW73022 EAW73023 Q9Y3V2 AA336253 AA336662 AA825527 AK292665 BAF85354 AK292699 BAF85388 AK296476 BAG59117 AL050062 CAB43254 AM392773 CAL37651 AM393257 CAL38135 BC010936 BC016307 BC065813 BC125142 AAI25143 BU858771 BX537497 BX648581 CA454169 CN306675 CR533493 CAG38524 DC409838 NM_001128142 NP_001121614 NM_001199682 NP_001186611 NM_001278247 NP_001265176 NM_001278248 NP_001265177 NM_015485 NP_056300 NR_103483 NR_103484 |
Function | Enhancer of SUMO conjugation. Via its interaction with UBE2I/UBC9, increases SUMO conjugation to proteins by promoting the: binding of E1 and E2 enzymes, thioester linkage between SUMO and UBE2I/UBC9 and transfer of SUMO to specific target proteins which include HIF1A, PIAS, NFKBIA, NR3C1 and TOP1. Isoform 1 and isoform 2 positively regulate the NF-kappa-B signaling pathway by enhancing the sumoylation of NF-kappa-B inhibitor alpha (NFKBIA), promoting its stabilization which consequently leads to an increased inhibition of NF-kappa-B transcriptional activity. Isoform 1 and isoform 2 negatively regulate the hypoxia-inducible factor-1 alpha (HIF1A) signaling pathway by increasing the sumoylation of HIF1A, promoting its stabilization, transcriptional activity and the expression of its target gene VEGFA during hypoxia. Isoform 2 promotes the sumoylation and transcriptional activity of the glucocorticoid receptor NR3C1 and enhances the interaction of SUMO1 and NR3C1 with UBE2I/UBC9. Has no |
Subcellular Location | Nucleus {ECO:0000269|PubMed:17956732}. Cytoplasm {ECO:0000269|PubMed:17956732}. Note=Colocalizes with UBC9/UBE2I in nuclear spots. |
Tissue Specificity | Isoform 1 and isoform 2 are expressed in glioma tumors (at protein level). Expressed in a wide number of tissues with highest expression in cerebellum, pituitary, heart, kidney, liver, stomach, pancreas, prostate and spleen. Low levels in thalamus, spinal cord, esophagus, thymus, lung and peripheral blood leukocytes. A higher level expression seen in pituitary tumors as compared to the pituitary gland. {ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:22009797, ECO:0000269|PubMed:23469069}. |
Human RWDD3 full length protein - ab132896 from Abcam
|
||||||||||
RWDD3 peptide - ab117773 from Abcam
|
||||||||||
RWDD3 Antibody Blocking Peptide - LS-E30782 from LifeSpan Bioscience
|
||||||||||
RWDD3 Antibody Blocking Peptide - LS-E30781 from LifeSpan Bioscience
|
||||||||||
RWDD3 Antibody Blocking Peptide - LS-E21719 from LifeSpan Bioscience
|
||||||||||
Recombinant Human RWDD3 Protein - H00025950-P01 from Novus Biologicals
|
||||||||||
RWDD3 Blocking Peptide - NBP1-76310PEP from Novus Biologicals
|
||||||||||
RWDD3 Blocking Peptide - NBP1-76309PEP from Novus Biologicals
|
||||||||||
RWDD3-Antibody-C-term-Blocking-Peptide - BP9363b from Abgent, a WuXi AppTec company
|
||||||||||
RWDD3 Peptide - GTX85245-PEP from GeneTex
|
||||||||||
RWDD3 Peptide - GTX85246-PEP from GeneTex
|
||||||||||
RWDD3 - H00025950-P01-10 from Acris Antibodies
|
||||||||||
RWDD3 - H00025950-P01-25 from Acris Antibodies
|
||||||||||
RWDD3 Peptide - 5409P from ProSci
|
||||||||||
RWDD3 Peptide - 5407P from ProSci
|
||||||||||
RWDD3 fusion protein - Ag18674 from Proteintech Group
|
||||||||||
RWDD3 fusion protein - ag18576 from Proteintech Group
|
||||||||||
RWDD3 (transcript variant 2) - TP325219 from Acris Antibodies
|
||||||||||
RWDD3 Protein - NBP1-92360PEP from Novus Biologicals
|
||||||||||
RWDD3 Peptide, Human - M34GP13704H from Creative Peptides
|